TQB2928 Injection Combined Anlotinib Hydrochloride Capsule in Recurrent/Metastatic Osteosarcoma and Other Solid Tumors
Launched by CHIA TAI TIANQING PHARMACEUTICAL GROUP NANJING SHUNXIN PHARMACEUTICAL CO., LTD. · May 30, 2024
Trial Information
Current as of February 08, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment approach for patients with recurrent or metastatic osteosarcoma (a type of bone cancer) and other solid tumors. Researchers want to see how well a combination of two medications—TQB2928 injection and anlotinib hydrochloride capsules—works in helping patients whose cancer has returned or spread after previous treatments. The trial is currently recruiting participants of all genders, aged between 18 and 70, who have high-grade osteosarcoma or certain types of liposarcoma that are not suitable for local treatment and have not responded to earlier therapies.
To participate, patients need to have already tried at least one round of chemotherapy for their condition, and their cancer must have either not improved or come back within six months after that treatment. It’s important to know that some patients, such as those with specific blood disorders or who have previously used certain cancer treatments, may not be able to join the trial. If eligible, participants can expect regular check-ups and monitoring throughout the study to assess how well the treatment works and its safety. This trial aims to provide valuable information that could help improve future cancer treatments.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Pathological diagnosis of high-grade osteosarcoma(cohort I),dedifferentiated liposarcoma or polytypic liposarcoma(cohort II),unsuitable for local treatment;
- * The requirements for front-line treatment received by subjects are as follows:
- • 1. Subjects with osteosarcoma have failed at least first-line chemotherapy and are not suitable for re-receiving first-line chemotherapy ,or progression within 6 months of the end of first-line therapy;
- • 2. Subjects with dedifferentiated liposarcoma or polytype liposarcoma who have received at least first-line chemotherapy failure for recurrent/metastatic sites or relapse during postoperative adjuvant chemotherapy or within 6 months after treatment(considered first-line treatment failure).
- Exclusion Criteria:
- • History of hemolytic anemia from any cause (including Evans syndrome) within 3 months prior to first dosing;
- • Subjects with osteosarcoma or dedifferentiated liposarcoma/polytype liposarcoma who have previously used antiangiogenic tyrosine kinase inhibitors (TKI) or bevacizumab or its biosimilar, such as anlotinib, apatinib, lenvatinib, sorafenib, sunitinib, regorafenib, fruquintinib;
- • Previous antibody or fusion protein or small molecule drug targeting CD47 or Signal-regulatory protein α (SIRRP-α).
About Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. is a prominent pharmaceutical company based in China, specializing in the research, development, manufacturing, and commercialization of innovative therapeutic solutions. With a strong commitment to advancing healthcare, the company focuses on a diverse range of therapeutic areas, including oncology, infectious diseases, and cardiovascular health. Leveraging cutting-edge technology and a robust R&D pipeline, Chia Tai Tianqing aims to enhance patient outcomes through high-quality pharmaceuticals and clinical trials that adhere to international standards. The company is dedicated to fostering collaborations and partnerships to drive medical innovation and improve global health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Beijing, Beijing, China
Changsha, Hunan, China
Tianjin, Tianjin, China
Beijing, Beijing, China
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0